Xiujun Zhang

Title: Xiujun Zhang: Innovator in HPV Therapeutic Vaccines

Introduction

Xiujun Zhang is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biomedicine, particularly in the development of therapeutic vaccines for human papillomavirus (HPV). His innovative work aims to enhance preventive and therapeutic measures against HPV-related tumors.

Latest Patents

Xiujun Zhang holds a patent for an HPV therapeutic nucleic acid vaccine. The nucleic acid sequences provided by this invention comprise sequence HPV16-AVLS1 and sequence HPV16-AVLC1 in a 1:1 ratio, as well as sequence HPV18-AVLS1 and sequence HPV18-AVLC1 in a 1:1 ratio. The sequences AVLS1 and AVLC1 include two concatenated E6 proteins, two LI short peptides, two L2 short peptides, two concatenated E7 proteins, one PADRE sequence, and one adjuvant sequence respectively. Notably, the N-terminal of sequence AVLS1 carries a mouse IgK secretion peptide sequence, while the N-terminal of sequence AVLC1 carries a ubiquitin sequence. This innovative nucleic acid vaccine can induce high titer antibodies against E6/E7 and elicit a robust functional cellular immune response, demonstrating excellent preventive and therapeutic effects against HPV-related tumors.

Career Highlights

Xiujun Zhang is associated with Beijing Aeonvital Biomedicine Research Co., Ltd., where he continues to advance his research in biomedicine. His work has garnered attention for its potential impact on public health, particularly in the fight against HPV.

Collaborations

Xiujun Zhang collaborates with notable colleagues, including Lei Liu and Jianming Tang. Their combined expertise contributes to the innovative research and development efforts at their institution.

Conclusion

Xiujun Zhang's contributions to the field of HPV therapeutic vaccines highlight his role as a key innovator in biomedicine. His work not only advances scientific knowledge but also holds promise for improving health outcomes related to HPV.